Author of

• 20195

  +

  P3.16 - Surgery (ID 732)

  • Event: WCLC 2017
  • Type: Poster Session with Presenters Present
  • Track: Surgery
  • Presentations: 1
  • Moderators:
  • Coordinates: 10/18/2017, 09:30 - 16:00, Exhibit Hall (Hall B + C)

  • 24273

    +

    P3.16-050 - Stromal PDGFR-β Expression Influences Postoperative Survival of NSCLC Patients Receiving Preoperative Chemo- or Chemo-Radiotherapy (ID 8871)

    09:30 - 09:30  |  Author(s): D. Eino
    • Abstract
    • Slides

    Background:
    Platelet-Derived growth factor beta (PDGFR-β) is a functional regulator of mesenchymal cells. It is reported that PDGFR-β is expressed by cancer associated fibroblasts, and PDGFR signaling supports cancer cells. Stromal expression of PDGFR-β is reported to be associated with poor prognosis in prostate, breast, pancreas, and gastric cancers. However, the significance of stromal PDGFR-β expression in non-small cell lung cancer (NSCLC) in patients undergoing preoperative chemo- or chemoradio-therapy had not been undetermined.
    
    Method:
    Seventy-two patients with NSCLC undergoing preoperative chemo- or chemoradio-therapy between 1996 and 2006 were assessed for expression of stromal PDGFR-β by immunohistochemistry using resected specimens. After cancer cells and stromal tissues were identified by HE staining, stromal PDGFR-β expression was defined as positive when it was observed in >5% of the stromal area. Relationships between stromal PDGFR-β expression and disease-free survival (DFS) and disease-specific survival (DSS) were analyzed.
    
    Result:
    The mean age of the 72 patients was 59.7 years. Sixty-one (85%) were male and 11 (15%) female. Forty patients (56%) underwent preoperative chemoradiotherapy and 32 patients (44%) underwent preoperative chemothearapy. Indications for preoperative chemotherapy were N2 disease in 51 (71%), T3 or T4 disease in 20 (28%), and other reasons in the remaining patient (1%). Regimens for preoperative chemotherapy were cisplatin (CDDP)-based in 34 patients (47%) and carboplatin (CBDCA)-based in 37 (52%). Type of resection were pneumonectomy in 7 (10%), bilobectomy in 6 (8%), lobectomy in 57 (79%), and sublobar resection in 2 (3%) patients. Complete resection were achieved in 59 patients (82%). The pathologic stage (7[th] ed.) was IA in 11 (15%), IB in 12 (17%), IIA in 6 (8%), IIB in14 (19%), IIIA in 19 (27%), IIIB in 5 (7%), and IV in 5 (7%) patients. The histological type were adenocarcinoma in 32 (44%), squamous cell carcinoma in 35 (49%), and others in 5 (7%) patients. On immunohitological examination, stromal cells expressed PDGFR-β in 47 cases (65%). Five-year DFS and DSS in the stromal PDGFR-β-positive group was significantly worse than in the negative group (29.1%-vs-64.6%, p=0.01 and 40.2%-vs-66.1%, p=0.02, respectively).
    
    Conclusion:
    Stromal PDGFR-β expression is negatively associated with DFS and DSS in patients with NSCLC undergoing preoperative chemo- or chemoradio-therapy.
    
    

    Only Active Members that have purchased this event or have registered via an access code will be able to view this content. To view this presentation, please login or select "Add to Cart" and proceed to checkout.